This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.
Recent advances in mass spectrometry-based proteomics have fostered a more precise, deep, and more functional look into clinical phenotypes. Going beyond traditional genomics, proteomics enables more relevant, quantitative, and informative understanding of diseases and treatments.
Jean-Marie Michot, a medical oncologist at Gustave Roussy Institute and Vito Dozio, Scientific Project Manager at Biognosys, will share a study that illustrates the promise of proteomics in understanding responses to new therapies such as anti-IL-6-based treatment and the impact of comorbidities on clinical outcomes.
They will discuss the results of a joint project in which serum from a cohort of patients infected with COVID-19 was submitted for analysis using the Biognosys HRM discovery proteomics platform. They will share details of proteomic profiles associated with clinical outcome, comorbidities, and the response to anti-IL6 treatment, which provide a comprehensive picture of the potential of using next-generation proteomics to enhance personalized medicine.
This webinar series will highlight recent advancements in the proteomics field and the impact of proteomics on clinical research in oncology.